NCT06021821

Brief Summary

This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group. All participants will complete a baseline questionnaire before completing their designated regime daily for six weeks. In addition, participants will complete study-specific surveys and validated questionnaires at the end of each week (Week 1, 2, 3, 4, 5 \& 6). The study will include 75 \[participants in total, 25 per group, who all have self-reported concerns around anxiety, stress, or depression. Questionnaires will be used to monitor sleep, cognitive ability, and changes in symptoms of anxiety, depression, and stress. Both study-specific questionnaires and validated questionnaires will be utilized, including the Generalized Anxiety Disorder Assessment (GAD-7), the 9-question Patient Health Questionnaire (PHQ-9), Perceived Stress Scale (PSS), and The World Health Organisation- Five Well-Being Index (WHO-5). Likert scale responses will be examined from baseline to each check-in. Participant responses on product feedback will be presented as % scores.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P25-P50 for not_applicable anxiety

Timeline
Completed

Started May 2023

Shorter than P25 for not_applicable anxiety

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 29, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 26, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 26, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 27, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 1, 2023

Completed
Last Updated

September 1, 2023

Status Verified

August 1, 2023

Enrollment Period

2 months

First QC Date

August 27, 2023

Last Update Submit

August 27, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change in scores on the Generalized Anxiety Disorder 7-item scale (GAD-7). [Baseline to Week 6]

    The GAD-7 is a self-report questionnaire used to assess the severity of generalized anxiety disorder. It consists of seven questions that ask about the frequency and intensity of common symptoms of anxiety over the past two weeks. Each question is scored on a scale from 0 to 3, with the total scores ranging from 0 to 21. The scoring is typically interpreted as follows: 0-4: Minimal anxiety 5-9: Mild anxiety 10-14: Moderate anxiety 15-21: Severe anxiety

    6 weeks

  • Change in scores on the Patient Health Questionnaire-9 (PHQ-9). [Baseline to Week 6]

    The PHQ-9 is a self-report questionnaire used to assess the severity of depression symptoms. Each question is scored on a scale from 0 to 3, with the total scores ranging from 0 to 27. The scoring is typically interpreted as follows: 0-4: Minimal depression 5-9: Mild depression 10-14: Moderate depression 15-19: Moderately severe depression 20-27: Severe depression

    6 weeks

  • Change in scores on the Perceived Stress Scale (PSS). [Baseline to Week 6]

    The PSS is a widely used self-report questionnaire designed to measure an individual's perception of stress in their life. Higher scores indicate higher perceived stress.

    6 weeks

  • Change in scores on the World Health Organization Well-Being Index (WHO-5). [Baseline to Week 6]

    The WHO-5, or World Health Organization Well-Being Index, is a self-reported questionnaire used to measure psychological well-being and mood. Respondents are asked to rate statements on a scale from 0 to 5, where 0 indicates "at no time" and 5 indicates "all of the time." The scores are summed, resulting in a total score that can range from 0 to 25. A total score of 0-13 suggests poor well-being and a higher risk of depression. A total score of 14-17 indicates moderate well-being. A total score of 18-25 suggests good well-being.

    6 weeks

Secondary Outcomes (1)

  • Changes in participant-perceived sleep quality. [Baseline to Week 6]

    6 weeks

Study Arms (3)

Intervention Group

EXPERIMENTAL

Participants will listen to the SoundMind app for 20 minutes per day, ideally during a moment of stress.

Other: SoundMind App

Spotify Group

ACTIVE COMPARATOR

Participants will listen to a specified Spotify playlist for 20 minutes per day, ideally during a moment of stress.

Other: Spotify Playlist

Control Group

NO INTERVENTION

This group will have no tasks prescribed.

Interventions

he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.

Intervention Group

Participants will listen to a "calm vibes" playlist by Spotify.

Spotify Group

Eligibility Criteria

Age18 Years - 28 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male or female
  • Between 18-28 years of age
  • Self-reported concerns around anxiety, stress, or depression
  • Generally healthy - don't live with any uncontrolled chronic disease
  • Must have headphones

You may not qualify if:

  • Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
  • Women who are pregnant, breastfeeding or attempting to become pregnant
  • Unwilling to follow the study protocol
  • Testing any other product for any other research studies at the same time
  • History of epilepsy or seizures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Citruslabs

Santa Monica, California, 90404, United States

Location

MeSH Terms

Conditions

Anxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Three-group study.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 27, 2023

First Posted

September 1, 2023

Study Start

May 29, 2023

Primary Completion

July 26, 2023

Study Completion

July 26, 2023

Last Updated

September 1, 2023

Record last verified: 2023-08

Locations